Palatin Technologies Inc. (PTN)

[mikedeatworld]

So come August, there are two obvious possibilities:

Sprout gets FDA approval, PTN sky rockets to $1.5-2

Sprout gets FDA denial, PTN falls to $.25-$.50

"Advisory committees provide FDA with independent opinions and recommendations from outside experts on applications to market new drugs, and on FDA policies. The marketing applications include data to show the safety and effectiveness of human drugs. The outside experts receive summary information about the applications and copies of FDA's review of the application documents. Based on this information, advisory committees may recommend approval or disapproval of a drug's marketing application. FDA generally follows an advisory committee's recommendation, but is not bound to do so. "


I've read a statistic, that suggested that the FDA has followed the advisory committee roughly 84% of the time. I can't find the link though, but that's decent odds for Sprout and that news should impact the value of PTN's stock. Does anyone have any data around FDA approval and the advisory committee's recommendations?


I do find this quote interesting:


www.fda.gov/downloads/drugs/newsevents/ucm423111.pdf

There is a drug, Bremelanotide, which very strong dopamine agonist that also has early positive benefits. So it would be incorrect to say there limited research in this area. It's just very poorly funded and we
desperately need more research.

LONG $PTN